Basal insulin

Insulin icodec

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

INS_ICODEC

Agent: insulin icodec
Dosing: titrated to target
Mechanism: Insulin glargine; detemir; degludec; icodec; NPH
Trials: 1
Participants in these arms: 645

Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.

Effects across outcomes

Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.

Condition	Outcome	Window	Versus	Effect (95% CrI)	SUCRA
Type 2 diabetes (adults)	Serious adverse events	longest follow-up	Placebo	HR 2.04 (0.99 to 4.26)	0.20
Type 2 diabetes (adults)	Serious adverse events	longest follow-up	Placebo	HR 1.93 (0.92 to 4.20)	0.18
Type 2 diabetes (adults)	Nausea	longest follow-up	Placebo	HR 0.48 (0.20 to 1.19)	0.86
Type 2 diabetes (adults)	Nausea	longest follow-up	Placebo	HR 0.50 (0.15 to 1.62)	0.73
Type 2 diabetes (adults)	Vomiting	longest follow-up	Placebo	HR 0.57 (0.19 to 1.56)	0.84
Type 2 diabetes (adults)	Vomiting	longest follow-up	Placebo	HR 0.60 (0.15 to 2.32)	0.76
Type 2 diabetes (adults)	Diarrhea	longest follow-up	Placebo	HR 0.74 (0.35 to 1.53)	0.80
Type 2 diabetes (adults)	Diarrhea	longest follow-up	Placebo	HR 0.80 (0.35 to 1.87)	0.72
Type 2 diabetes (adults)	Constipation	longest follow-up	Placebo	HR 0.26 (0.08 to 0.81)	0.89
Type 2 diabetes (adults)	Constipation	longest follow-up	Placebo	HR 0.30 (0.09 to 0.98)	0.84

Trials

COMBINE 1
A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Once Weekly Insulin Icodec, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately Controlled With Daily Basal Insulin.
2022 · 1,291 randomized · 52 weeks

Insulin icodec

Related

Effects across outcomes

Trials